Although this column is running in The Cancer Letter, where we turn for timely insights and information relevant to the cancer community, I suspect that a lot of our readers are watching college basketball this week.
Technological innovations are often hailed as transformative tools capable of revolutionizing healthcare. From gene editing for conditions like sickle cell disease to AI predicting hospital readmissions, to telemedicine expanding healthcare access, these advancements have the potential to change the way we treat diseases.
I was really excited to get to talk about the role that mentorship plays in women’s leadership development. It’s a topic that I’ve thought a lot about, and also that I’ve benefitted from, and that I think is not always applied with enough intention. There is an art to mentorship, and I want to share some of how that has helped me navigate career transitions and pivot to leadership roles.
As we are all aware, the new presidential administration is moving rapidly to change how science, including health sciences, will be conducted and funded by the federal government, including research supported by the National Institutes of Health.
As a physician-scientist who has navigated drug development from lab bench to bedside to executive boardroom, I want to touch upon a subject that is near and dear to my heart: the state of American science—a linchpin of our healthcare system and national competitiveness.
As cancer specialists, we have to constantly be on the lookout, alert for trends as they emerge—because they might impact the way we best deliver advice or care, or because trends may inform us about specific influences that drive cancers.
Knowledge is power, and this information, true for many cancers, is valuable for everyone to know—either to have an awareness of their own bodies and the factors that they can control, or to create spaces for empathy with persons they might encounter with cancer.
As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments. Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were... […]
Today, our world is small. It feels smaller all the time. In a few hours we can get to any point on the globe.
As cancer clinicians, we spend years learning how to think objectively and rationally when supporting patients who have responded to a cancer diagnosis with anger and fear.
